On January 31, 2020, Yoshino, T.; Cleary, J. M.; Van Cutsem, E.; Mayer, R. J.; Ohtsu, A.; Shinozaki, E.; Falcone, A.; Yamazaki, K.; Nishina, T.; Garcia-Carbonero, R.; Komatsu, Y.; Baba, H.; Argiles, G.; Tsuji, A.; Sobrero, A.; Yamaguchi, K.; Peeters, M.; Muro, K.; Zaniboni, A.; Sugimoto, N.; Shimada, Y.; Tsuji, Y.; Hochster, H. S.; Moriwaki, T.; Tran, B.; Esaki, T.; Hamada, C.; Tanase, T.; Benedetti, F.; Makris, L.; Yamashita, F.; Lenz, H.-J. published an article.Recommanded Product: 65-71-4 The title of the article was Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. And the article contained the following:
The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) vs. placebo in patients with refractory metastatic colorectal cancer. This post hoc anal. investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clin. outcomes. A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc anal. using the entire RECOURSE population to determine the correlations between CIN and clin. outcome. We then carried out a similar anal. on the J003 trial to validate the results. In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS vs. those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS vs. those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients.NCT01607957 (RECOURSE).JapicCTI-090880 (J003). The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4
The Article related to metastatic colorectal cancer neutropenia survival trifluridine tipiracil, ftd/tpi, j003, recourse, chemotherapy-induced neutropenia, metastatic colorectal cancer, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 65-71-4
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia